Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Synlogic, Roche in Bowel-Disease Collaboration

06/17/2021 | 05:56am EDT

By Matt Grossman

Synlogic Inc. and Roche Holding AG will collaborate on research into a treatment for inflammatory bowel disease, Synlogic said Thursday.

Following the research period established by the agreement, Roche will have an exclusive option for a licensing and collaboration agreement for further development and commercialization, according to Synlogic, a Cambridge, Mass. based pharmaceutical company.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

06-17-21 0756ET

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING AG 0.89% 347.6 Delayed Quote.12.49%
SYNLOGIC, INC. 1.56% 3.26 Delayed Quote.50.93%
All news about ROCHE HOLDING AG
01:03aPRESS RELEASE : FDA accepts application for -3-
DJ
01:03aPRESS RELEASE : FDA accepts application for -2-
DJ
01:03aPRESS RELEASE : FDA accepts application for Roche's faricimab for the treatment ..
DJ
01:03aROCHE : FDA accepts application for Roche's faricimab for the treatment of neova..
AQ
01:01aPRESS RELEASE : Data for Roche's Evrysdi(R) -2-
DJ
01:01aPRESS RELEASE : Data for Roche's Evrysdi(R) (risdiplam) published in New England..
DJ
01:01aROCHE : FDA Accepts Application for Genentech's Faricimab for the Treatment of W..
BU
01:00aROCHE : Data for Roche's Evrysdi« (risdiplam) published in New England Journal o..
AQ
07/28ROCHE : Data for Genentech's Evrysdi (risdiplam) Published in New England Journa..
BU
07/27ROCHE : Societe Generale Lifts Price Target on Roche, Maintains Hold Recommendat..
MT
More news
Financials
Sales 2021 60 753 M 66 774 M 66 774 M
Net income 2021 14 459 M 15 891 M 15 891 M
Net cash 2021 4 697 M 5 162 M 5 162 M
P/E ratio 2021 20,4x
Yield 2021 2,70%
Capitalization 304 B 332 B 334 B
EV / Sales 2021 4,92x
EV / Sales 2022 4,76x
Nbr of Employees 101 465
Free-Float 83,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 347,60 CHF
Average target price 375,75 CHF
Spread / Average Target 8,10%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG12.49%332 374
JOHNSON & JOHNSON9.40%454 682
PFIZER, INC.18.04%235 663
NOVARTIS AG-0.44%221 987
ELI LILLY AND COMPANY46.00%221 420
ABBVIE INC.10.64%208 344